A2M

1.42%

$6.23 the a2 milk company limited

What is the concern about labeling changes?! Would have thought...

First 3 Last

Share
Profile

Follow
Yeoda

549 Posts.

4

26/08/16

11:18

Post #: 18705891
Share

Originally posted by shiva84 ↑

A2 Milk Co. (A2M.AX): FY16: Infant formula in good shape; retain CL-Buy
24 Aug 2016 at 4:51pm AEST
What's changed
A2M reported FY16 EBITDA of NZ$54.6mn, 1.5% above GSe. NPAT was 7% below GSe on tax given the higher US/UK losses which are not tax deductible. The company provided limited guidance for FY17.
Implications
Key takeaways: (1) Excluding US/UK, EBITDA was 15% ahead of GSe. Similar to the BAL result, infant formula growth boosted profit in ANZ and China and was above us on higher margins – which we view as sustainable into FY17E; (2) The US however was below our expectations. A2M flagged a cumulative US$20-25mn of investment in next 2-3 years, US$10mn greater than GSe; (3) Read-throughs from BKL’s weak outlook commentary? Based on industry contacts and data, we believe that changes to Chinese regulations in April/May caused some disruption to cross-border trade for both vitamins/supplements and infant formula. However, as we have highlighted previously, the regulatory framework for infant formula is more evolved and is at this stage clearer than the regulatory framework for vits/supps. Our contacts suggest that inventory issues for vits/supps are not as concerning as for infant formula, although we will continue to monitor this closely, particularly ahead of required labelling changes. Retain CL-Buy: Excluding US/UK, A2M is trading on 19x/16x FY17E/FY18E P/E, a 10%/18% discount to the ASX 200 Industrials ex-Financials, an attractive multiple given its growth prospects vs. risk profile in our view.
Valuation
We increase our 12-month target price (85% weight for equal blend of DCF and EV/GCI, 15% weight for M&A valuation) to A$2.35/NZ$2.45 from A$2.15/NZ$2.25 (in-line with our upgrades to ANZ and China), on FY17E/FY18E EPS changes of -7%/3%.
Key risks
(-) Safety and quality risks; intense competition from other foreign brands; adverse regulatory outcomes in China.

Expand

What is the concern about labeling changes?! Would have thought this wouldn't have any impact. What are your thoughts?

A2M Price at posting: $1.95 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

BUX

Buxton projects new graphite province discovery at WA Narryer play

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

There are more pages in this discussion • 5 more messages in this thread...

First 3 Last

Add A2M (ASX) to my watchlist

(20min delay)
Last $6.23		Change -0.090(1.42%)		Mkt cap ! $4.510B

Open	High	Low	Value	Volume
$6.30	$6.31	$6.17	$6.785M	1.089M

Buyers (Bids)

No.	Vol.	Price($)
1	5458	$6.23

Sellers (Offers)

Price($)	Vol.	No.
$6.24	13490	1

View Market Depth

No.	Vol.	Price($)
2	5025	6.210
1	484	6.200
1	1000	6.150
5	9029	6.100
1	1652	6.050

Price($)	Vol.	No.
6.260	1604	1
6.280	10000	1
6.300	1750	1
6.320	700	1
6.350	2000	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

A2M (ASX) Chart

What is the concern about labeling changes?! Would have thought...

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

What is the concern about labeling changes?! Would have thought...

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News